Phase II study of retifanlimab in patients with recurrent locally advanced or metastatic Merkel cell carcinoma (POD1UM-201).

Grignani G, Rutkowski P, Lebbé C, Guida M, Gaudy-Marqueste C, Spagnolo F, Burgess M, Morano F, Montaudié H, Depenni R, Spada F, Yeung CCS, Pulini J, Cornfeld M, Tian C, Bhatia S

Open source

DOI: 10.1136/jitc-2025-012478
Published: 2025 Aug 11
Container: Journal for immunotherapy of cancer
Publisher: Not recorded
Open access: yes

Credibility signals

uncertain Score 53/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
supportingDirectory of Open Access Journals: A matching record was returned by DOAJ. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1136/jitc-2025-012478,
  title = {Phase II study of retifanlimab in patients with recurrent locally advanced or metastatic Merkel cell carcinoma (POD1UM-201).},
  author = {Grignani G and Rutkowski P and Lebbé C and Guida M and Gaudy-Marqueste C and Spagnolo F and Burgess M and Morano F and Montaudié H and Depenni R and Spada F and Yeung CCS and Pulini J and Cornfeld M and Tian C and Bhatia S},
  year = {2025},
  journal = {Journal for immunotherapy of cancer},
  doi = {10.1136/jitc-2025-012478},
  url = {https://doi.org/10.1136/jitc-2025-012478}
}

RIS

TY  - JOUR
TI  - Phase II study of retifanlimab in patients with recurrent locally advanced or metastatic Merkel cell carcinoma (POD1UM-201).
AU  - Grignani G
AU  - Rutkowski P
AU  - Lebbé C
AU  - Guida M
AU  - Gaudy-Marqueste C
AU  - Spagnolo F
AU  - Burgess M
AU  - Morano F
AU  - Montaudié H
AU  - Depenni R
AU  - Spada F
AU  - Yeung CCS
AU  - Pulini J
AU  - Cornfeld M
AU  - Tian C
AU  - Bhatia S
PY  - 2025
JO  - Journal for immunotherapy of cancer
DO  - 10.1136/jitc-2025-012478
UR  - https://doi.org/10.1136/jitc-2025-012478
ER  -

APA

G, G., P, R., C, L., M, G., C, G., F, S., M, B., F, M., H, M., R, D., F, S., CCS, Y., J, P., M, C., C, T., & S, B. (2025). Phase II study of retifanlimab in patients with recurrent locally advanced or metastatic Merkel cell carcinoma (POD1UM-201).. Journal for immunotherapy of cancer. https://doi.org/10.1136/jitc-2025-012478

Source records

pubmed · retrieved 2026-09-26T11:00:51.701Z
europe-pmc · retrieved 2026-09-26T11:00:51.732Z
doaj · retrieved 2026-09-26T11:00:51.694Z